Relmada Therapeutics Inc RLMD

CORAL GABLES, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that senior management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference being held in Boston, MA, from September 8 - 10, 2026. Wells Fargo 21st Annual Healthcare Conference DetailsFormat: One-o

Relmada Therapeutics Inc (RLMD) reports robust NDVO1 efficacy and a solid cash runway, but manufacturing delays push IND filing to end of 2026.

Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational program upon IND clearance.Sepranolone IND filing expected by year-end 2026 and initiation of Phase 2 proof-of-concept study in Prader-Willi Syndrome upon IND clearance. Strengthened the leadership team with appointment of Bipin Dalmia as Chief Business Officer.Added to the Russell 2000® and Russell 3000® Indexes effective June 2

Brings nearly three decades of leadership spanning NMIBC, corporate strategy and business development to help advance NDV-01 and support the Company's long-term growth and value creation. CORAL GABLES, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Bipin Dalmia, PhD, MBA, as Chie

CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM ET to discuss financial results for the second quarter ended June 30, 2026, and recent business progress. Conference Call and Webcast Information: Date: Th

CORAL GABLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that the Company joined the Russell 2000® Index and the Russell 3000® Index effective after the U.S. market closed on June 26, 2026, as part of the Russell Indexes reconstitution. The Russell 3000® is a leading benchmark for broad U.S. eq

Relmada Therapeutics Inc. (NASDAQ:RLMD) is one of the best growth stocks under $30 to buy now. On May 12, Relmada Therapeutics reported Q1 2026 results, highlighted by positive 12-month Phase 2 data for its NDV-01 candidate, which showed a 95% complete response rate in high-risk non-muscle invasive bladder cancer. The company is well-capitalized with $234 […]

Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building on his tenure as Chief Scientific Officer at Sage Therapeutics. CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Michael Quirk

CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held in New York, NY, from June 2-4, 2026. Jefferies Global Healthcare Confere

Relmada Therapeutics Inc (RLMD) showcases robust clinical data and strategic financial moves, despite facing increased expenses and net loss.

Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and a 94% CR rate at any time and a durable 80% CR rate at 12 months in the BCG-unresponsive subpopulation, reinforcing best-in-class potential in NMIBCOn track to initiate Phase 3 RESCUE registrational program in second line (2L) BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026Filed p